Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the united states before human papillomavirus vaccine recommendations

Sexually Transmitted Diseases

Volumn 40, Issue 7, 2013, Pages 534-538

  Camenga, Deepa R ^a   Dunne, Eileen F ^b   Desai, Mayur M ^c,d   Gee, Julianne ^e   Markowitz, Lauri E ^b   Desiliva, Ajit ^f   Klein, Nicola P ^f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c YALE UNIVERSITY   (United States)

^d ROBERT WOOD JOHNSON FOUNDATION   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ADULT DISEASE; ARTICLE; CHILD; CONDYLOMA ACUMINATUM; FEMALE; HUMAN; INCIDENCE; INTEGRATED HEALTH CARE SYSTEM; MAJOR CLINICAL STUDY; MALE; PENIS; RECTUM; RECURRENT DISEASE; SCHOOL CHILD; UNITED STATES; UTERINE CERVIX; VAGINA; VULVA; CLASSIFICATION; COHORT ANALYSIS; CONDYLOMATA ACUMINATA; IMMUNOLOGY; PAPILLOMA VIRUS; PENILE DISEASES; SEXUALLY TRANSMITTED DISEASES, VIRAL; URETHRAL DISEASES; UTERINE CERVICAL DISEASES; VACCINATION; VAGINAL DISEASES; VIROLOGY; VULVAR DISEASES; YOUNG ADULT;

ADOLESCENT; ADULT; CALIFORNIA; CHILD; COHORT STUDIES; CONDYLOMATA ACUMINATA; DELIVERY OF HEALTH CARE, INTEGRATED; FEMALE; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; PENILE DISEASES; SEXUALLY TRANSMITTED DISEASES, VIRAL; URETHRAL DISEASES; UTERINE CERVICAL DISEASES; VACCINATION; VAGINAL DISEASES; VULVAR DISEASES; YOUNG ADULT;

EID: 84888631796     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3182953ce0     Document Type: Article

References (30)

1. Scarbrough Lefebvre CD, Van Kriekinge G, Goncalves MA, et al. Appraisal of the burden of genital warts from a healthcare and individual patient perspective. Public health 2011; 125:464-475.
2. Jeynes C, Chung MC, Challenor R. 'Shame on you'Vthe psychosocial impact of genital warts. Int J STD AIDS 2009; 20:557-560.
3. Wang KL, Jeng CJ, Yang YC, et al. The psychological impact of illness among women experiencing human papillomavirusYrelated illness or screening interventions. J Psychosom Obstet Gynaecol 2010; 31:16-23.
4. Chesson HW, Blandford JM, Gift TL, et al. The estimated direct medical cost of sexuality transmitted diseases among American Youth, 2000. Perspect Sex Reprod Health 2004; 36:11-19.
5. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36:1397-1403.
6. Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: Incidence and risk factors in a cohort of university students. J Infect Dis 2007; 196:1128-1136.
7. Mao C, Hughes JP, Kiviat N, et al. Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol 2003; 188:677-684.
8. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008; 198:827-835.
9. Nielson CM, Harris RB, Dunne EF, et al. Risk factors for anogenital human papillomavirus infection in men. J Infect Dis 2007; 196: 1137-1145.
10. Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital wartsYrelated healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004; 31:748-752.
11. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-2):1-24.
12. CDC. Recommendations on the use of quadrivalent human papillomavirus vaccine in malesVAdvisory Committee on Immunization Practices (ACIP), 2011. MMWR. Morb Mortal Wkly Rep 2011; 60:1705-1708.
13. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection inmen (HIM): Acohort study. Lancet 2011; 377:932-940.
14. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ 2010; 341:c3493.
15. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401-411.
16. Hoy T, Singhal PK, Willey VJ, et al. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009; 25:2343-2351.
17. Oriel JD. Natural history of genitalwarts. Br J Vener Dis 1971; 47:1-13.
18. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191:731-738.
19. Aral SO, Hughes JP, Stoner B, et al. Sexual mixing patterns in the spread of gonococcal and chlamydial infections. Am J Public Health 1999; 89:825-833.
20. Hillemanns P, Gabrielle Breugelmans J, Gieseking F, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: A cross-sectional study. BMC Infect Dis 2008; 8:76.
21. Fleischer AB Jr, Parrish CA, Glenn R, et al. Condylomata acuminata (genital warts): Patient demographics and treating physicians. Sex Transm Dis 2001; 28:643-647.
22. Chuang TY, Perry HO, Kurland LT, et al. Condyloma acuminatum in Rochester, Minn., 1950-1978. I. Epidemiology and clinical features. Arch Dermatol 1984; 120:469-475.
23. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: Diagnosis, treatment, and prevention. Clin Infect Dis 2002; 35(suppl 2):S210-S224.
24. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: Analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44.
25. Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: Achievements and challenges. Prev Med 2011; 53(suppl 1):S29-S35.
26. Read TRH, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87:544-547.
27. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine-effectiveness in reducing genital warts: An analysis of California Public Family Planning Administrative claims data, 2007-2010. Am J Public Health 2012; 102:833-835.
28. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: Perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998; 9:571-578.
29. Brackbill RM, Sternberg MR, Fishbein M. Where do people go for treatment of sexually transmitted diseases? Fam Plan Perspect 1999; 31:10-15.
30. Civic D, Scholes D, Grothaus L, et al. Adolescent HMO enrollees' utilization of out of plan services. JAdolesc Health 2001; 28:491-496.